Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes

Anticipated Profits From Biosimilar Candidates To Expand Future Development

Executive Summary

Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.

You may also be interested in...



Formycon Concludes Successful Development Of Stelara Biosimilar Ahead Of Annual Results

Formycon has successfully concluded the development of its ustekinumab biosimilar FYB202, with regulatory submissions planned for Q3. It is just one of many biosimilar candidates which the German firm expects to soon start making significant revenue contributions.

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

Fresenius Kabi And Formycon Ally On Stelara Rival

Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel